anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The present invention relates to: transformed bacteria in which genes having anticancer functions are transduced in bacteria; a method for producing the same; and a composition including the same for improving radiation treatment for cancer. More specifically, cytolysin genes are transduced in D. radiodurans, so that transformed bacteria which secrete cytolysin which is an anticancer material are produced. It has been confirmed that the produced transformed bacteria secrete cytolysin, and anticancer killing effects of the secreted cytolysin have been confirmed in vitro and in vivo. The cytolysin-secreting genetically modified bacteria are non-pathogenic radiation-resistant bacteria which are moved for only in vivo cancer cells as a target. The method of the present invention can be used along with an existing radiation technique having accompanying side effects, so that cancer tissues can be effectively killed and prevented from being metastasized with minimum radiation. Moreover, when coating is performed using a natural polymer capsule including bacteria which secrete anticancer materials, the composition of the present invention can be used as an anticancer agent which can be orally administrated.
Cisplatin is an antineoplastic medicine used in the treatment for various types of cancer. Among its side effects is ototoxicity, which may result in a bilateral and irreversible hearing loss. The ototoxic effect in the pediatric population has a bigger impact as it compromises language acquisition. The discovery of drugs with otoprotective effects and the optimal way to administer them have become significant challenges in minimizing the impact of cisplatin regarding auditory function. The objective was to understand otoprotective drugs and their relevance in the preventive treatment to cisplatin-induced ototoxicity in childhood. An integrative review was conducted by consulting databases including PubMed, Bireme, MedLine, LILACS, SciELO, and ClinicalTrials.gov. The search strategy was performed by crossing descriptors (DeCS and MeSH) and free terms. Studies published in English, Spanish, and Portuguese were selected, with no publication year restrictions. Subsequently, articles were selected according to inclusion and exclusion criteria. A total of 736 articles were found in PubMed, 431 in Bireme, 425 in MedLine, 6 in LILACS, 0 in SciELO, and 4 in ClinicalTrials.gov. After document analysis, 12 articles were selected for full analysis. Evidence was found for 8 substances with potential otoprotective effects when used with cisplatin, which tend to minimize the impact of cisplatin regarding auditory function. The substances found were: Amifostine, Dexamethasone, Genistein, Ginkgo Biloba, Lycopene, N-acetylcysteine, Polydatin also Sodium Thiosulfate. In general, these drugs are applied before, during, or after cisplatin infusion, depending on the chosen drug, via intravenous, oral, or transtympanic injections, acting as antioxidant therapy. The biochemical effects of these substances are relevant to their potential otoprotective properties, including the inactivation of oxygen free radicals and electrophilic platinum species. The use of these substances can reduce ototoxicity, decreasing cisplatin-induced hearing loss and improving the confort of life, especially for children.
Provided is an antivirus composition. The antivirus composition comprises a compound represented by general formula (I) or a pharmaceutically acceptable salt thereof. R 1  represents a halogen atom or a C 1-6  alkyl group which may be substituted with a halogen atom. R 2  represents a hydrogen atom or a C 1-6  alkyl group. Q is a group selected from -C(O/S)-C=C-R 3 , -C(O/S)-NH-CH 2 -R 3  and -C(O/S)-R 4 . R 3  represents a C 1-6  alkyl group, a C 1-6  alkoxy group, a hydroxyl group or a monocyclic heteroaromatic ring group or phenyl group which may be substituted with a halogen atom. R 4  represents a C 1-6  alkyl group, a C 1-6  alkoxy group, a hydroxyl group or a halogen-substituted phenyl group or monocyclic heteroaromatic ring group. W represents a saturated monocyclic or bicyclic nitrogen-containing heterocyclic group which includes one nitrogen and 5 to 9 carbons as ring atoms.
Studies have shown that integrating eye exercises with neck strengthening exercises has a significant effect in managing symptoms associated with visual disturbances and neck pain. For instance, a study conducted in 2024 to investigate the effect of oculomotor exercises in patients having chronic neck pain. Based on the result, they found that incorporating oculomotor exercises along with conventional exercises into treatment plan can significantly improve gaze stability, proprioception, visual acuity and fatigue in chronic neck pain patients. In 2023 study investigate the effectiveness of manual techniques for the management of FHP. They found that sub-occipital muscle energy technique is effective in improving CVA, cervical range of motion and postural alignment. study conducted in 2023 investigated the comparative effect sub-occipital muscle energy technique vs sub-occipital release in mechanical neck pain and FHP population. They concluded that group receiving MET show significant improvement in CVA, NDI and Cervical ROMs. Another research concluded that Sub-occipital muscle energy technique incorporating with proprioceptive training are effective in improving joint position sense (proprioception) and CVA in FHP population. A study evaluate the effectiveness of eye exercises on computer vision syndrome. They concluded the ocular exercises are effective in reducing visual fatigue symptoms such as eye itching, dryness and headache.

This research is innovative as it explores the interconnected roles of ocular muscles and sub-occipital muscles on visual fatigue, proprioception, and postural imbalances, particularly in FHP patients. As Literature suggest that tightness of suboccipital affect somatosensory input and proprioceptive information crucial for head and eye coordination. Thus, offering a comprehensive view of how FHP and visual fatigue are interconnected. Furthermore, the integration of oculomotor exercises in managing FHP-related visual fatigue is an underexplored as the existing literature primarily focuses on the musculoskeletal consequences of forward head posture and ocular exercises for visual disturbance without exploring the interaction between these factors. This research aimed to bridge the existing gap in literature by providing evidence-based guidance on the effectiveness of METs and oculomotor exercises in the management of visual symptoms associated FHP.
<P>PROBLEM TO BE SOLVED: To provide a diagnostic agent and a medicine for decreasing the production of an amyloid β protein, thereby preventing or suppressing conditions liable to develop AD.  <P>SOLUTION: A blood cholesterol level is correlated with production of Aβ, and is a predictor of a population at risk of developing AD. The method for lowering a blood cholesterol level can be used to decrease the production of Aβ, and thereby decrease the risk of developing AD. The method and compositions can also be used for treating an individual diagnosed with AD. The method includes administration of compounds which increase uptake of cholesterol by the liver (such as an HMG CoA reductase inhibitor), administration of compositions which block endogenous cholesterol production (such as an HMG CoA reductase inhibitor), administration of compositions which prevent uptake of dietary cholesterol, and administration of combinations of any of these which are effective to lower a blood cholesterol level.  <P>COPYRIGHT: (C)2010,JPO&INPIT
PROBLEM TO BE SOLVED: To obtain a parasiticide for hatchery fish which has fine decomposability in seawater, shows safe and high effects without being remained and accumulated in marine organisms and is useful in the extermination of parasites, e.g. gill flake of yellow tail (Heteraxine heterocerca), Benedemia seriola and the like in hatchery fishes, e.g. Fugu rubripes and the like, by including peracetic acid as an active ingredient. SOLUTION: This parasiticide is obtained by including peracetic acid as an active ingredient. For example, gill flake of yellow tail (Heteraxine heterocerca), Benedemia seriola and the like can be exterminated at 8 ppm or more and 35 ppm or more, respectively, in the concentration of peracetic acid. It is favorable to include hydrogen peroxide and acetic acid as stabilizers in this medicine. In exterminating parasites, this medicine is preferably neutralized with an alkali to use.
OBJECTIVE: There is limited research on neurocognitive outcome and associated risk factors in long-term, adult survivors of childhood acute lymphoblastic leukemia (ALL), without treatment of cranial radiation therapy. Moreover, the impact of fatigue severity and pain interference on neurocognition has received little attention. In this cross-sectional study, we examined neurocognitive outcome and associated factors in this population.
METHOD: Intellectual abilities, verbal learning/memory, processing speed, attention, and executive functions were compared to normative means/medians with one sample t tests or Wilcoxon signed-rank tests. Associations with risk factors, fatigue severity, and pain interference were analyzed with linear regressions.
RESULTS: Long-term, adult survivors of childhood ALL (N = 53, 51% females, mean age = 24.4 years, SD = 4.4, mean = 14.7 years post-diagnosis, SD = 3.4) demonstrated above average intellectual abilities, but performed below average in attention, inhibition, processing speed, and shifting (p < 0.001). Executive functioning complaints were significantly higher than normative means, and positively associated with fatigue (p < 0.001). There was no interaction between sex and fatigue and no neurocognitive impairments were associated with pain interference, risk group, age at diagnosis, or sex.
CONCLUSIONS: Long-term, adult survivors of ALL treated without cranial radiation therapy, demonstrate domain-specific performance-based neurocognitive impairments. However, continued research on the neurocognitive outcome in this population as they age will be important in the coming years. Executive functioning complaints were frequently in the clinical range, and often accompanied by fatigue. This suggests a need for cognitive rehabilitation programs.
After treatment with Cetuximab (Cetux) and Irinotecan (Irin), Dalotuzumab (Dmab) was administered as an intravenous infusion at 10 mg/kg in Cycle 1 on Days 22, 29 and 36; followed in subsequent cycles by treatment with 10 mg/kg on Days 1, 8, 15, 22, 29 and 36. Each cycle was 6 weeks long.
Peripheral arterial disease is the third leading entity of atherosclerosis. The femoropopliteal segment is affected in most patients. Endovascular revascularisation is one possible treatment option, but high rates of restenosis, especially in complex lesions, are a limiting factor. Bare-metal stents failed to show a long-term superiority in a Cochrane systematic review. Another approach to prevent restenosis is local delivery of an antiproliferative drug (e.g. Paclitaxel) via Drug-Coated Balloon Angioplasty. New studies did report their results since the publication of earlier meta-analyses. It's time for an up-to-date systematic review. Prior systematic reviews did not address risk of bias nor did they take differences in treatment strategy despite the used balloon catheter into consideration.Some previous reviews did compare results from different points in time, e.g. analysis of 6 months' results together with 24 months' results.
Hemophagocytic lymphohistiocytosis (HLH) has been described for decades in association with malignancies (M-HLH). While its mechanism is unknown, M-HLH has a poor prognosis, ranging from 10% to 30% overall survival. Mature T-cell lymphomas, diffuse large B-cell lymphoma, and Hodgkin lymphoma, with or without viral co-triggers such as Epstein-Barr virus, are among the most frequent underlying entities. Most M-HLH cases occur at the presentation of malignancy, but they may also occur during therapy as a result of immune compromise from chemotherapy (HLH in the context of immune compromise, IC-HLH) and (typically) disordered response to infection or after immune-activating therapies (Rx-HLH, also known as cytokine release syndrome, CRS). IC-HLH typically occurs months after diagnosis in the context of fungal, bacterial, or viral infection, though it may occur without an apparent trigger. Rx-HLH can be associated with checkpoint blockade, chimeric antigen receptor T-cell therapy, or bispecific T-cell engaging therapy. Until recently, M-HLH diagnosis and treatment strategies were extrapolated from familial HLH (F-HLH), though optimized diagnostic and therapeutic treatment strategies are emerging.
An healthspan life obey older adults to adhere to an active ageing lifestyle because it combat the natural cognitive and physical losses associated with ageing (1-3). Exercise programs have shown to be effective interventions for healthspan (2) and its attendance is high recommended by health organizations (4). Several studies have analyzed the beneficial effects of exercise programs on physical and cognitive performance of older adults, and they concluded that multimodal programs involving both physical and cognitive stimulation are more benefic than single physical or cognitive program interventions (5). Dance involves both physical and cognitive stimulation, since the participants are engaged physical, intellectually, and emotionally tasks(6). Dance explore the movement elements (body, space, time, dynamic, and relationships) and particularly the Creative Dance explore it through tasks that allow the participants to create their own movements and express ideas and feelings through body language (7). In Creative dance, tasks can be simplified according to specificities/limitations of participants and considering a holist approach (6). This dance do not require any dance technique or prior training, and promote socioemotional interactions, stimulating positive feelings, joy, and pleasure; furthermore, is a safe practice, not requiring expensive resources (6). For these reasons, Creative Dance is becoming gradually recommended for older people by investigators (6-9). In fact, Creative Dance seems to increase proprioception (8), several physical fitness parameters (7, 9), mobility (9) and life satisfaction (7) of older people. Thus, although there are only few studies in Creative Dance for older adults, this form of dance seems to be a pertinent practice to revert their usual process of loss and decline of motor and mental skills (6). We hypnotized, that a Creative Dance program may contribute to the community-dwelling older adults' healthspan, particularly we hypnotized that such program may induce improvements on physical fitness, on body awareness, and on rhythm perception and reproduction, as well to promote improvements on well-being indicators.
Patients undergo 3-dimensional conformal radiotherapy (3D-CRT) or intensity-modulated radiotherapy (IMRT) 5 days a week for 6-6.5 weeks. Patients also receive cisplatin IV over 60 minutes on days 1, 8, 15, 22, 29, 36, and 43 during radiotherapy.
This study is a randomized, placebo-controlled, single blind clinical trial. Seventy patients with ESRD on chronic HD and a functioning AVF will be recruited. Consent form will be obtained. History and physical, dialysis parameters and laboratory data (CBC, CMP, PTT \& INR) will be obtained throughout the study. The following data will be documented on each patient: 1-Age/gender/race/body weight/cause of ESRD 2-Vintage of HD 3-Time since access was placed 4-Type and place of access and blood flow rate of access 5-History of prior access problems 6-Comorbid conditions (Hypertension, coronary artery disease, Diabetes Mellitus, Bleeding problems, peripheral vascular disease). 7-Current medications (Coumadin, Erythropoiesis stimulating agents, heparin, other antiplatelets, digoxin, statins). Patients will be randomized into two groups to receive: Group 1: Ticagrelor 90 mg PO BID Group 2: Placebo drug PO BID.

Subjects will have a screening visit and if they qualify for the study they will have 18 additional visits. All of these visits will occur while the subjects are at their normal dialysis treatment. Subjects will be randomized to either the Ticagrelor group or the placebo group. Subjects will be on study medication for 6 months then they will have a follow up period off drug for 6 months. Subjects will be seen twice a month while on study medication and once a month in the follow up period. While the subjects are on study medication the study team will assess any side effects of the study medication and put their relation to the study drug at each study visit. The study team will use clinical monitoring as suggested by Beathard (21). The study team will document the subject's adherence to the study, if they are hospitalized and what caused their hospitalization. A monthly intra-access flow will be obtained using ultrasound dilution by transonics as part of standard of care. Any change in the clinical assessment of the access, prolonged bleeding (\>20 minutes) after removal of needles, trend of decreasing intra-access blood flow as determined by transonic (\> 25% or original flow), or an access flow rate \< 400 ml/min, will prompt a referral for a fistulogram. If confirmed stenosis (\>50% stenosis of the access diameter) an intervention (angioplasty) will be performed. This intervention is part of the subjects standard of care.
The invention discloses a wet regenerative burn tincture which is prepared by putting 80 to 120 grams of cornu bubali, 20 to 50 grams of trichosanthes root, 20 to 50 grams of angelica dahurica, 10 to 30 grams of zhiren, 30 to 80 grams of ophiopogon root, 30 to 80 grams of dried rhizome of rehmannia, 5 to 30 grams of fiveleaf akebia and 30 to 100 grams of kimihide into clear water, decocting the mixture for one hour with slow fire and filtering the mixture. The invention has the functions of clearing away heat and toxic material, diminishing inflammations, relieving pain, removing rottenness and promoting muscle and has good effects on treating burn. The burn wound surfaces can be regenerated in situ without scars, disability, granulation hyperplasia or pigmentation. The burn can be treated fast without pain, wound surface scabs fall off automatically, the behaviors of a patient for relieving the bowels and having meals and the mental state can not be affected during treatment. The invention integrates Chinese and western treatment and adopts wetting and drying cycle of the burn wound surfaces. The treatment is not exposure treatment or blocking treatment. The wound surfaces are transparent and clear. The burn tincture has short treatment period and low treatment cost, thus a burn patient has low pressure on economy and mentality, and the patient can recovery fast.
BACKGROUND: Treatment options are limited, and the prognosis is poor for patients with platinum-resistant recurrent metastatic (R/M) head and neck squamous cell carcinoma (HNSCC). This study evaluated the efficacy and safety of a paclitaxel and ifosfamide (TI) regimen in patients with R/M HNSCC whose disease had progressed following platinum-based therapy.
PATIENTS AND METHODS: In this retrospective study, we included 53 patients with R/M HNSCC who underwent at least one cycle of TI-based therapy, post platinum failure, between February 2020 and August 2023. Some patients received the TI regimen in combination with immunotherapy and/or cetuximab. Key metrics assessed included the objective response rate (ORR), disease control rate, and progression-free as well as overall survival.
RESULTS: The study observed an ORR of 15.8% and a disease control rate of 36.8%. The median progression-free survival for the entire cohort was 3.3 months, and the median overall survival was 9.6 months. Notably, the combination of TI with immunotherapy yielded a higher ORR of 30.8%, compared to 14.3% with TI alone. The most prevalent grade 1-2 adverse events were anemia (81%), weight loss (68%) and hypernatremia (55%).
CONCLUSION: The TI-based regimen demonstrated favorable efficacy and safety profile in treating R/M HNSCC. Enhanced outcomes may be attainable when combining it with immunotherapy. This study suggests that TI-based therapy could serve as a potential salvage option for this specific patient group.
OBJECTIVES: I. Determine the safety of gadolinium texaphyrin administered prior to whole brain radiotherapy in patients with brain metastases. II. Compare the efficacy and toxicity of whole brain radiotherapy with or without gadolinium texaphyrin in these patients. III. Assess the quality of life of these patients.

OUTLINE: This is a randomized, two stage, multicenter study. Patients are stratified according to RTOG recursive partitioning analysis class (RPA class 1 vs class 2) and tumor type (breast vs lung vs other). Stage 1 (lead-in): All patients receive gadolinium texaphyrin IV over 5-10 minutes on the 10 days that they receive radiotherapy. Approximately 2-5 hours later, patients undergo whole brain radiotherapy. Stage 2 (randomization): Patients are randomized to one of two treatment arms. Patients in arm I undergo whole brain radiotherapy for 10 days. Patients in arm II receive gadolinium texaphyrin and radiotherapy as in stage 1. Quality of life is assessed on days 10 and 28, then monthly for 5 months, and then every 3 months thereafter. Patients are followed at day 28, then monthly for 5 months, and then every 3 months until death.

PROJECTED ACCRUAL: The lead-in phase will accrue at least 25-30 patients and the randomization phase will accrue 400 patients (200/arm) over a 12 month period.
The aim of this study is in children diagnosed with Cerebral Palsy (CP); It is a comparative study of the effects of treadmill and bicycle ergometer applications combined with total immersive virtual reality (TISG) on motor function, balance and walking. 34 cases diagnosed with Cerebral Palsy between the ages of 12-18 and attending a rehabilitation center will be included in the study. The sample will be divided into two groups by randomization (TİSG combined with treadmill group n = 17, TİSG combined with bicycle ergometer group = 17). Evaluations will be made before and at the end of treatment. An exercise program that will last 45 minutes twice a week for six weeks will be applied to both study groups. The treadmill combined with TİSG group will be given walking training on the treadmill in a virtual environment using virtual reality glasses. The TISG and combined bicycle ergometer group will be given exercise training on the bicycle ergometer in a virtual environment using virtual reality glasses. For both groups, this process will continue in the same order for each exercise in the session. It is assumed that performing the bicycle ergometer in a sitting position makes this exercise safe, easier to perform, and can be performed at different levels of motor function, regardless of the severity of motor impairment. Based on this assumption, this study aimed to compare the use of bicycle ergometer combined with TISG with the treadmill combined with TISG in improving functional capacity, balance and walking functions in children with CP.